TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

NCT03387917 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
OTHER
Sponsor class

Stopped The premature termination is based on the unexpectedly low patient accrual to the clinical trial and the strategic considerations in the development of the TLD-1 after having included 13 out of 14 patients in the comparative PK part.

Conditions

Interventions

Sponsor

Swiss Cancer Institute